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Abstract
The Polish Council for Control of Iodine Deficiency Disorders (PCCIDD) was established in 1991 in Krakow at the Chair and Dept. of 
Endocrinology, Jagiellonian University, Collegium Medicum, following the example of the International Council for Control of Iodine 
Deficiency Disorders (ICCIDD) in Charlottesville, USA. The PCCIDD co-operates with the European Co-ordinating Centre in Pisa, Italy. 
The PCCIDD comprises a group of experts in endocrinology, iodine prophylaxis, the technology of salt and food iodisation, and Polish 
representatives of several organisations: WHO, UNICEF, the Polish Consumers Federation, and the Spokesman for Children’s Rights.
The strategic goal of the Polish Council is to solve the problem of iodine deficiency in Poland realising the Programme for Elimination of 
Iodine Deficiency financed by the Ministry of Health. The Polish model of iodine prophylaxis contains obligatory iodisation of household 
salt (20–40 mg KI/1 kg) and neonates’ formula (10 µg/100 mL of milk), and additional supplementation for pregnant and breastfeeding 
women with 150–200 µg of iodine as pharmacotherapy.
The model is very effective: endemic goitre in schoolchildren has been eradicated, the prevalence of goitre in pregnant women has fallen 
from 80% to 19%, the frequency of transient hypothyroidism in neonates has dropped from 2.0% to 0.16%, and the observed increase of 
incidence rate of thyroid cancer in women over 40 years old has diminished markedly. In 2008, a WHO Collaborating Centre (WHOCC) 
for Nutrition was designated at the Department of Endocrinology, UJCM in Krakow. The main goal of the WHOCC is to sustain effective 
iodine prophylaxis in Poland in the light of the latest WHO recommendations on the necessary reduction of daily salt intake as a risk fac-
tor for hypertension and arteriosclerosis. Therefore, additional standardised carriers of iodine (milk, mineral water) have been introduced 
into the food market. (Pol J Endocrinol 2012; 63 (2): 156–160)
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Streszczenie
Polska Komisja ds. Kontroli Zaburzeń z Niedoboru Jodu została powołana przy Klinice Endokrynologii UJCM w Krakowie, na wzór 
Międzynarodowej Komisji ds. Kontroli Zaburzeń z Niedoboru Jodu (ICCIDD) w Charlotesville (Stany Zjednoczone). W skład Polskiej 
Komisji wchodzą eksperci z dziedziny endokrynologii, technologii jodowania produktów spożywczych oraz polscy reprezentanci organizacji 
międzynarodowych: WHO, UNICEF, Federacji Konsumentów oraz Biura Rzecznika Praw Dziecka. Głównym zadaniem Polskiej Komisji jest 
realizacja Programu Eliminacji Niedoboru Jodu finansowanego przez Ministerstwo Zdrowia. Polski model profilaktyki jodowej polega na 
obowiązkowym jodowaniu soli kuchennej (20–40 mg KI/1 kg), formuły noworodków (10 µg/100 ml mleka) oraz dodatkowej suplementacji 
kobiet w ciąży i kobiet karmiących w dodatkowa dawkę jodu 150–200 µg/dzień. Model ten okazał się bardzo efektywny. Wole endemiczne 
u dzieci szkolnych zostało całkowicie wyeliminowane, częstość wola u kobiet w ciąży zmniejszyła się z 80% do 19%, częstość przejściowej 
niedoczynności tarczycy u noworodków obniżyła się z 2,0% do 0,16%, a obserwowany wzrost częstości raka tarczycy u kobiet powyżej 
40. roku życia wydatnie się obniżył. W 2008 roku przy Klinice Endokrynologii UJCM w Krakowie powołano Ośrodek Współpracujący 
z WHO (WHOCC) w zakresie Żywienia. Głównym zadaniem Ośrodka jest utrzymanie efektów profilaktyki jodowej w świetle ostatnich 
rekomendacji WHO na temat konieczności zmniejszenia spożycia soli jako czynnika ryzyka nadciśnienia tętniczego i miażdżycy. W tej 
sytuacji na rynek żywnościowy wprowadzono dodatkowe nośniki jodu — mleko i wody mineralne. (Endokrynol Pol 2012; 63 (2): 156–160)
Słowa kluczowe: niedobór jodu, jodowanie soli, profilaktyka jodowa
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Introduction
The Polish Council for Control of Iodine Deficiency Dis-
orders (PCCIDD) was established in 1991 in Krakow by 
the Polish Society of Endocrinology upon consultation 
with the Ministry of Health as a consulting body to the 
Minister of Health with respect to iodine deficiency. 
The Council has joined a group of similar organisations 
in Europe and in the world, and co-operates with the 
European Co-ordinating Centre in Pisa, Italy, (Prof. 
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A. Pinchera) and the International Council for Control 
of Iodine Deficiency Disorders (ICCIDD) in Charlottes-
ville, USA.
The strategic goal of the Polish Council is to solve the 
problem of iodine deficiency at a population level by 
implementing the programme designed by the Council 
— the National Programme for Elimination of Iodine 
Deficiency — and in this way fulfilling the declaration 
that Poland signed at the World Health Assembly in 
New York in 1990. The Council is located at the Chair 
and Department of Endocrinology, Jagiellonian Uni-
versity, Collegium Medicum,University Hospital in 
Krakow, and is affiliated at the Polish Society of Thyreol-
ogy in Łódż. The chairman of the Council and co-ordi-
nator of the Programme is Prof. Zbigniew Szybiński — 
ICCIDD expert.
The discontinuation of iodine prophylaxis during 
Martial Law in Poland in 1980 produced certain health 
consequences on the population level: an increased 
incidence of goitre in schoolchildren — in some areas 
up to 41% [1], an increased incidence of goitre in adults 
of up to 30% [2] and in pregnant women of up to 80% 
[3, 4], transient hypothyroidism in neonates of up to 
2.0% [5, 6], and a 3–5-fold increase in the incidence 
of differentiated thyroid carcinomas in women over 
40 years of age [7]. The PCCIDD decided to carry out 
epidemiological studies in 1992/1993 involving school 
children, neonates and pregnant women [1, 3], and took 
part in 1994 in an international campaign by the ICCIDD 
and WHO entitled ‘Thyromobil’ aimed at school chil-
dren [8]. In compliance with the ICCIDD standards, the 
PCCIDD defined iodine deficiency in Poland as moder-
ate, and only in the coastal area as slight. The studies 
also revealed that the Carpathian and Sudeten endemics 
could progress to become severe endemics.
The model of iodine prophylaxis in Poland
In 1996, because of the endemic situation, the PCCIDD 
proposed to the Ministry of Health mandatory kitchen 
salt iodisation (20–40 mg KI/1 kg), and this disposition 
was put into operation at the beginning of 1997. The 
Council defined the remaining components of the Pol-
ish model of iodine prophylaxis: additional iodisation 
of formula for neonates (10 µg/100 ml of milk) and ad-
ditional pharmacotherapy 150 µg I/daily in pregnant 
and breastfeeding women [9].
The Ministry of Health approved the National Pro-
gramme for Elimination of Iodine Deficiency in 1999– 
–2003 assuming that the final analysis of the programme 
would identify new tasks of the programme [10]. The 
consecutive years 1999, 2000, 2001 and 2002 witnessed 
a significant improvement in all study indicators: the in-
cidence of goitre in schoolchildren decreased by 30–80% 
compared to 1992/93, and in the youngest group of 6– 
–8 year olds, it was 2.6% on average, i.e. below endemic 
level [11]. The incidence of thyreotropinaemia in neo-
nates over 20 mUI/mL decreased from 2.0% to 0.16% 
[5, 6], the incidence of goitre in pregnant women fell 
from 80% to 19% [12], and the progress rate of differentiated 
thyroid carcinoma in women was also decreased [13]. The 
findings were approved by the conference of experts 
from ICCIDD, UNICEF and WHO held at the Ministry 
of Health on 1 February 2002, and the Polish model 
was considered as effective and safe. There was no 
population risk of iodine-induced hyperthyroidism 
and hypersensitivity due to iodine consumption [14]. 
However, the final goals of the programme have not 
been achieved. In older schoolchildren, goitre still oc-
curs in 7–8% with regional variability, and frequency 
of ioduria over 100 µg I/L has not reached the desired 
value of 50% [15]. No more than 70% of pregnant 
women receive the recommended iodine dose [8], 
and although the progress rate of thyroid carcinoma 
in women is slower, its incidence is still 3–4 times 
higher than in 1990 [7]. The quality of salt iodisation 
has reached 96% of the normal limits [16].
The National Programme for Elimination of Iodine 
Deficiency Disorders was interrupted between 2003 and 
2005, although the disposition on mandatory iodisation 
of kitchen salt and neonatal TSH screening according 
to the ICCIDD recommendation [17] continued. The 
Programme was put into operation again in 2006, and 
continues today.
The Chair and Department of Endocrinology, Col-
legium Medicum, Jagiellonian University in Kraków 
— head Prof A. Hubalewska Dydejczyk MD PhD — is 
the chair of the Polish Council for Control of Iodine 
Deficiency Disorders, which is an advisory body of the 
Ministry of Health. University Hospital in Krakow is 
the financial co-ordinating centre of the Programme 
for Elimination of Iodine Deficiency in Poland. The 
principal co-ordinator of the National Programme 
for Elimination of Iodine Deficiency in Poland is Prof. 
Zbigniew Szybiński MD, PhD, chairman of the PCCIDD, 
and expert of the International Council for Control of 
Iodine Deficiency Disorders (ICCIDD). The project 
manager is M. Trofimiuk MD, PhD [10]. The Depart-
ment of Endocrinology has continuously co-ordinated 
and supervised the Programme since 1992.
Co-operation with the  
World Health Organisation (WHO)
Europe is an iodine deficiency area. Only 13 of 40 Euro-
pean countries apply mandatory iodisation of salt and 
iodine deficiency remains a serious public health prob-
lem. However, Poland is now in the group of European 
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countries with optimal supplementation of iodine at the 
population level [18, 19]. The main carrier of iodine in 
the prophylactic system is iodisation of household salt. 
The World Health Organisation (WHO) issued a recom-
mendation, the Technical Consultation: Paris 2006 [20], 
Luxembourg 2007 [21] that increased salt consumption, 
as a risk factor for hypertension and atherosclerosis, 
should be restricted.
The European Commission looked to adhere to this 
recommendation by creating the High Level Group 
on Nutrition and Physical Activity. According to WHO 
recommendations, a daily allowance of 5 g NaCl (i.e., 
2 g Na) for individual salt consumption should not be 
exceeded [20]. This has been confirmed in clinical stud-
ies [22–25]. In Poland, preventive measures were also 
undertaken [27–29]. The National Food and Nutrition 
Institute in Warsaw issued a Position Statement [30] on 
the general strategy of salt intake reduction in Poland. 
Accordng to WHO’s data, daily intake of NaCl in Eu-
ropean countries is from 8 to 10 g/day/person [20]. At 
present, mean individual salt consumption in Poland 
totals 13.5 g, of which salt used in households constitutes 
8.8 g [26]. The results of the population based study 
in Poland on prevalence of goitre [14–16], resulted in 
mandatory iodisation of household salt with 20–40 mg 
KI/1 kg, and iodisation of neonates’ formula introduced 
in 1997 [17, 18]. An additional dose of 150 µg of iodine is 
recommended for pregnant women [19, 20]. This model 
is very effective, and endemic goitre in schoolchildren 
has been eradicated [15]. The main indicators of the 
effectiveness of iodine prophylaxis are: thyroid vol-
ume, concentration of iodine in urine, and neonatal 
TSH in serum [19]. To evaluate the actual situation in 
terms of the prevalence of goitre in schoolchildren, we 
devised the new normative values of thyroid volume 
measured by means of USG in a selected group of 6– 
–12 year-old schoolchildren from the Polish coastal re-
gion without goitre and with UI over 100 µg/L [31]. Cur-
rent efforts aimed at preventing iodine-deficiency look 
to increase consumption of other iodine-rich products, 
mainly milk [32], and mineral water with standardised 
levels of iodine [14].
Once they achieve an iodine concentration of 
0.1–0.2 mg/L, these products can easily supplement 
any decrease in physiological iodine levels resulting 
from reduced salt consumption. Also required are 
wide-ranging educational campaigns which will 
be co-ordinated by the WHO Collaborating Centre 
for Nutrition at the Department of Endocrinology 
at Jagiellonian University, Collegium Medicum in 
Krakow [33], set up in 2008. Its main terms of refer-
ence focus on iodine prophylaxis and the necessity 
of increasing consumption of alternative iodine-rich 
products such as milk and iodised mineral water with 
a controlled concentration of iodine of 0.1–0.2 mg/L. 
These products can easily supplement any decrease 
of iodine daily intake resulting from reduced salt 
consumption, and may become a constant component 
of the everyday diet [14].
Iodine prophylaxis and its effectiveness in Poland 
are co-ordinated and controlled by the Polish Council 
for Control of Iodine Deficiency Disorders within the 
National Programme for Elimination of Iodine Defi-
ciency financed by the Polish Ministry of Health.
Description of the Programme  
for Elimination of Iodine Deficiency
Task 1
Prevalence of goitre and urinary iodine concen-
tration in children: the ‘Thyromobil’ campaign
Performer: University Hospital in Krakow, Chair and 
Department of Endocrinology, Collegium Medicum, 
Jagiellonian University; Prof. Filip Gołkowski MD, PhD
Methods
The Thyromobil van is equipped with a USG device 
(Siemens Sonoline I–400 and a 7.5 MHz linear ar-
ray transducer). Thyroid volume is calculated as the 
sum of both lobe volumes according to the formula: 
width × depth × length × 0.479 = V (mL), without 
isthmus. The prevalence of goitre is calculated according 
to the reference values of the WHO/ICCIDD 1997 stand-
ard. All examinations are performed by experienced 
doctors under the supervision of the co-ordinating 
centre headed by a person trained by the ICCIDD. The 
casual morning urine samples taken from each child are 
collected, deep frozen, and sent to the laboratory under 
the supervision and control of the referencing labora-
tory at the Institute of Food and Nutrition in Warsaw. 
Additionally, a special questionnaire concerning thyroid 
pathology and iodine intake in everyday diet is filled 
out, with the help of parents.
Task 2
Incidence of goitre and ioduria  
in pregnant women
Performer: Clinical Hospital No 3 Medical Univer-
sity, Department of Thyreology in Łodz; Prof. Andrzej 
Lewiński MD, PhD
Pregnant women belong to a major risk group, and 
the study of the incidence of goitre and ioduria in preg-
nancy is important. Analysis carried out in 2002 revealed 
a significant decrease in goitre prevalence in pregnant 
women, from 80% in 1990 to 19% in 2002. A question-
naire administered by the Institute of Mother and Child 
revealed that 40% of pregnant women in Poland did not 
receive iodine supplementation.
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Methods
Iodine urinary concentration is determined using the 
Sandell-Kolthoff method in co-operation with the control 
laboratories, as above. A USG device is equipped with 
a 7.5 MHz linear array transducer. Thyroid volume is 
calculated as the sum of both lobe volumes according to 
the formula: width × depth × length × 0.479 = V (mL), 
without isthmus. Thyroid hormones (total and free frac-
tion) are determined by means of the LIA–MAT system 
(Byk-Sangtec, Dietzenbach, Germany); anti-TPO and 
anti-TGB antibodies are detected by means of electrohe-
miluminiscency method — system Roche.
Task 3
Analysis of TSH level in neonates
Performer: Institute of Mother and Child, Warsaw; 
Ass. Prof. Mariusz Ołtarzewski MD, PhD
Neonatal screening (300,000–400,000 neonates per 
year) covers over 90% of the country. Within the Pro-
gramme of Elimination of Iodine Deficiency, we analyse 
the frequency of TSH level corresponding to so-called 
transient hypothyroidism in neonates (5–20 IU/mL).
Methods
TSH in the blood of neonates is determined between 2– 
–5 days of life by means of Neonatal TSH LIA-MAT 
system (Byk-Sangtec, Dietzenbach, Germany). Ques-
tionnaires (6,000–8,000 per year) on the frequency of 
additional supplementation with iodine in the course of 
pregnancy will be distributed among pregnant women 
in whom blood was sampled for TSH measurements.
Task 4
Registry of thyroid carcinoma
Performer: University Hospital in Krakow, Chair and 
Department of Endocrinology; Prof. Alicja Hubalewska 
Dydejczyk MD, PhD
The standardised registry of thyroid carcinoma will 
be continued in 11 centres: Szczecin, Gdańsk, Olsztyn, 
Białystok, Poznań, Warsaw, Łódź, Gliwice, Rzeszów, 
Kraków, and Nowy Sącz, covering a population of more 
than 16 million. The incidence rate of thyroid cancer is 
calculated as the number of newly-diagnosed thyroid 
cancers based on the classification ICD-10 per 100,000 
inhabitants per year.
Task 5
Quality control of salt and neonates’ formula 
iodisation; consumption level of kitchen salt
Performer: Institute of Food and Nutrition, Warsaw; 
Prof Katarzyna Stoś PhD
The Institute of Food and Nutrition established a refer-
ence laboratory to measure iodine levels in kitchen salt. 
The role of the programme is to control the execution of the 
disposition of the Ministry of Health. Monitoring kitchen 
salt consumption at the population level is a strategic is-
sue in the face of the necessity of reducing daily intake as 
a preventive measure against hypertension.
Methods
The concentration of KI in kitchen salt samples (300– 
–400 per year) and on the consumer and producer lev-
el will be examined by means of the Sandell-Kolthoff 
method.
Task 6
Post-graduate teaching and health promotion  
on iodine supplementation in pregnancy
Performer: Chair and Department of Endocrinology, 
Jagiellonian University, Collegium Medicum in Krakow; 
Prof. Zbigniew Szybiński, MD, PhD
Within the framework of post-graduate teaching 
in all districts of the country will be organised lectures 
on iodine deficiency and prophylactic measures in 
pregnancy, targeting primary health care physicians, 
endocrinologists and gynaecologists. In accordance with 
this action, suitable materials will be published and sent 
to radio and TV programmes.
Summary
The Polish Council for Control of Iodine Deficiency 
Disorders accredited at the Department of Endocrinol-
ogy, UJCM in Krakow, is the body of experts tasked 
with realising the National Programme for Elimination 
of Iodine Deficiency.
The Council’s work has resulted in organisation 
of an effective model of iodine prophylaxis that has 
brought about the eradication of endemic goitre in 
schoolchildren and optimal supplementation of iodine 
at the population level.
Designated at the Department of Endocrinology, 
UJCM in Krakow, the WHO Collaborating Centre for 
Nutrition realises the new model of iodine prophylaxis, 
adhering to the latest WHO recommendations on the 
necessary reduction of daily salt intake.
*Polish Council for Control of Iodine Deficiency Disorders: 
Z. Szybiński, Dept. of Endocrinology, Jagiellonian University, 
Collegium Medicum in Krakow; A. Hubalewska-Dydejczyk, Dept. 
of Endocrinology, Jagiellonian University, Collegium Medicum 
in Krakow; F. Gołkowski, Dept. of Endocrinology, Jagiellonian 
University, Collegium Medicum in Krakow; J.B. Starzyk, Dept. of 
Paediatric and Adolescent Endocrinology, Jagiellonian University, 
Collegium Medicum, Krakow; D. Lemańska, Macroregional Labora-
tory for Screening Investigastion University, Paediatric Hospital 
in Krakow Jagiellonian University, Collegium Medicum in Krakow; 
E. Przybylk-Mazurek, Dept. of Endocrinology, Jagiellonian Uni-
versity, Collegium Medicum in Krakow; A. Milewicz, Polish Endo-
crinologic Association, Dept. of Endocrinology, Diabetology and 
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Isotopic Treatment, Medical Academy in Wrocław; A. Noczyńska, 
Dept. of Endocrinology and Developmental Age Medical Acad-
emy in Wroclaw; A. Lewiński, Polish Association of Thyreology, 
Country Consultant in Endocrinology, Dept. of Endocrinology and 
Metabolic Diseases, Center of Health of the Mother-Pole, Medical 
University in Łódź; M. Karbownik-Lewińska, Dept. of Oncologic 
Endocrinology, Medical University in Łódź; S. Radowicki, Country 
Consultant in Endocrinology, Dept. of Gynecology and Obstetrics, 
Medical University in Warsaw; J. Nauman, M. Mossakowski Dept. 
of Endocrinology of the Institute of Clinical and Experimental 
Medicine, Polish Academy of Science, Dept. of Internal Diseases 
and Endocrinology Warsaw Medical University, Central Clinical 
Hospital; E. Bandurska-Stankiewicz, Endocrinology, Diabetology 
and Internal Diseases, Warmia–Mazury, University in Olsztyn; 
M. Górska, Dept. of Endocrinology, Diabetology and Internal Dis-
eases, Medical Academy in Białystok; R. Junik, Dept. of Endocrinol-
ogy and Diabetology in Bydgoszcz, Kopernik Medical University 
in Toruń; E. Malecka-Tendera, Dept. of Paediatrics, Endocrinology 
and Paediatric Diabetology, Silesian Medical University in Katowice; 
M. Ruchała, Department of Endocrinology, Metabolism and Internal 
Diseases, Poznan University of Medical Sciences; M. Niedziela, Dept. 
of Pediatric Endocrinology and Rheumatology, Poznan University of 
Medical Sciences; A. Syrenicz, Dept. of Endocrinology, Metabolic and 
Internal Diseases in Szczecin; D. Birkholz, Dept. of the Paediatrics, 
Haematolgy, Oncology and Endocrinology, Instytut of Pediatrics, 
Medical Academy in Gdańsk; M. Grzywa, Regional Consultant in 
Endocrinology for Rzeszów; M. Jarosz, National Food and Nutrition 
Institute in Warsaw, Department of Nutrition and Dietetics with the 
Clinic of Metabolic Diseases and Gastroenterology, National Food 
and Nutrition, Institute in Warsaw; K. Stoś, Institute for Food and 
Nutrition in Warsaw; L. Szponar, Institute for Food and Nutrition 
in Warsaw; M. Ołtarzewski, Screening and Hormonal Investigation 
Laboratory Institute of Mother and Child in Warsaw; B. Jarząb, Dept. 
of Nuclear Medicine and Oncologic Endocrinology, M. Skłodowska- 
-Curie Center for Oncology, Dept. in Gliwice; F. Brzóska, Dept of 
Animal Feeding and Fodder, Instytut of Zootechnics; K. Ślizowski, 
Polish Academy of Science, Institute of Economy of the Resources 
of Minerals and Energy, Expert of Salt Iodization; P. Miśkiewicz, 
WHO Office Connecting with the Ministry of Health; K. Kissimo-
va-Skarbek, IDF Senior Health Economics Specialist; E. Borowiecka, 
Polish National Committee for UNICEF; M. Michalak, Spokesman 
of Children Rights, Office of the Spokesman of Childre Rights; 
K. Pluskwa-Dąbrowski, President of Polish Consumers’ Federation; 
Michał Bożek; Małgorzta Kusztal; Kajetan d’Obyrn; Krzysztof Zieba; 
HONORARY MEMBERS: M. Rybakowa, M. Gembicki, I. Kinalska, 
B. Huszno, T. Romer, J. Sowinski, B. Dorant, R. Wąsik
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